Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist - Wikidata - wikimedia - TriplyDB

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

http://www.wikidata.org/entity/Q39151730

about

Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists Differential role of Hedgehog signaling in human pancreatic (patho-) physiology: An up to date review Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors Not so Fast: Co-Requirements for Sonic Hedgehog Induced Brain Tumorigenesis Hedgehog signaling inhibitors as anti-cancer agents in osteosarcoma Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer.Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies.Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis.Hedgehog pathway blockade with the cancer drug LDE225 disrupts taste organs and taste sensation.Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics.Identification of Small Molecules Which Induce Skeletal Muscle Differentiation in Embryonic Stem Cells via Activation of the Wnt and Inhibition of Smad2/3 and Sonic Hedgehog Pathways.Hedgehog acyltransferase as a target in pancreatic ductal adenocarcinoma.A crucial requirement for Hedgehog signaling in small cell lung cancer Molecular pathways: the hedgehog signaling pathway in cancer.Small molecule Hedgehog pathway antagonists.Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.Targeted therapy for advanced Basal-cell carcinoma: vismodegib and beyond Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas.Matching mice to malignancy: molecular subgroups and models of medulloblastoma.Small molecule inhibitors of the hedgehog signaling pathway for the treatment of cancer.Toward a systems-level understanding of the Hedgehog signaling pathway: defining the complex, robust, and fragile.Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problems Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies.Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.Hedgehog signaling in cancer stem cells: a focus on hematological cancers.Hedgehog inhibitors: a patent review (2013 - present).Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice SHH inhibitors for the treatment of medulloblastoma.Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.Quinolone-1-(2H)-ones as hedgehog signalling pathway inhibitors.

P2860

Q24632161-7F9999C0-72EB-44DC-A0C6-46561CAB2CBA Q26748692-772BC03D-881F-4044-BF4F-B9A9FACCDEEC Q26764892-5662FA36-3FD8-4528-8554-6E7ED33E99BF Q26799880-89A72448-28FE-4DCF-9B0E-E2EF0F61A40F Q26992348-B35E7928-F52B-4E94-AB6C-88BBCA1A8BFC Q28072902-750D7AE6-D573-4646-B8F3-C1A66E79FD98 Q28078947-AAC32DA8-05FA-43C7-BCCB-D5AC5CE7045C Q33687409-715AA0E0-D47A-4A9D-A226-8F97D907FA0F Q34244929-BAC5D905-4678-457C-A9E6-2F804A0D6A70 Q34374039-95366958-8F50-491E-A5C5-EAB518B5E45E Q34589094-456BDC84-CE16-4B6C-AC16-DBA7C58E6BB5 Q35026699-6A22FBCF-B8DA-4CFA-94F3-5E1E8CDFD74B Q35034980-83CAE44E-3512-4E96-99E9-197A2A1AA4CC Q35205627-FDD5E4C1-B775-4CEB-A5F0-344F194AC168 Q35756696-14BD9155-3F11-40B5-B603-EE52A2A8F4A7 Q35844189-28B49704-C665-4831-9973-C22F4C6B825C Q35885427-03E8E68E-5542-4B0F-A9AB-3C31EABA7651 Q36050816-B76C9C03-0F43-4C35-B3CA-EE7DCF8786B2 Q36243790-835233FF-9F44-4754-B0CE-E063B15E9E18 Q36314340-85BED342-F671-4BD1-954B-12BB85820CD3 Q36408686-B057C4A2-BDD5-4328-BAEF-65E14521A7EA Q36447756-E9C04E13-43BE-4F01-8E57-CB8726045DA4 Q36457457-EE49867B-19F1-4770-B0F3-6ECCD80F796D Q36474588-5E2992EF-F983-49A0-BD2A-42F56DE6B25F Q36881957-BEDA068F-7F9F-49CB-A73A-3A22DD477418 Q36917768-9DF13C33-30D3-4C35-9ADE-9AF8F5B6D865 Q36923522-D627D8B6-4316-44E4-BFC9-6C6C7ED752D6 Q37714065-75E1F85D-182B-4376-87A8-B23B841D75F5 Q37982341-9066A88E-976A-47C3-B4BE-F64273561D6C Q38039960-EC6D35EC-8C39-497A-8E45-F8671155EC0B Q38051564-0D85B4E6-77BB-4E4E-9AE5-5C7CF80AA57F Q38076275-30C25AB0-BB36-4752-8AAD-9A7A95C6649A Q38213666-FDC45A8F-347B-453C-8233-25577B0B85DD Q38339385-97D2C2FD-0EC5-4ED2-BFCD-9EF0987C6500 Q38359705-F1B9D783-B014-426B-9991-64738C86C583 Q38366266-14298C2C-FBDE-4A7C-A132-2927D452A547 Q38430202-2ED21789-3C6A-4AF4-A53C-E26CF9C28417 Q38509205-EB27B50B-EDB6-411D-A5CA-3A9711AA99D8 Q38605886-129F1186-422F-40A7-8F4E-A668112D7B1D Q38766060-8F009F28-914B-4703-B4BE-25A16DD6929C

P2860

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

http://www.wikidata.org/entity/Q39151730

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

@en

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.

@nl

type

label

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

@en

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.

@nl

prefLabel

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

@en

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.

@nl

P1433

Q39151730-3A5F06B9-29F2-445F-B362-56FB02B47F09

P1476

Q39151730-9E9F0600-205E-4B41-A0AC-F85A36E7C1B0

P2093

Q39151730-0A4FDDE8-E8DD-438D-AA5B-E2CEF9FCC10E

Q39151730-0E30C9E6-44CD-40E2-BB20-09DEE82948AC

Q39151730-2351B3B2-4665-458A-9D77-EE1267124230

Q39151730-315FBFE5-E62B-46DD-BE6C-1F7EEF34C53C

Q39151730-3DE70185-F956-4126-87F5-39DF2A79DC94

Q39151730-3E4EDA3E-6450-4A22-B7DB-36B342B5794A

Q39151730-415FC598-2EB0-4D87-AD47-6D621A99C11F

Q39151730-416EAFE8-47F0-4710-96EF-6AAD70BD5E75

Q39151730-41F35C3D-C139-40B6-84E3-78D4D2DE7C2F

Q39151730-4934BCE8-34E4-4843-8E33-739C3C4A3608

P2860

Q39151730-187F0DB4-3111-4F15-A798-54702211F3ED

Q39151730-1EBBF19C-727F-4CA9-A60A-9D068E3456FA

Q39151730-363C2C0D-5EF1-43C8-8B2E-FC46895BC645

Q39151730-4321D66A-07DC-4FD8-85A2-75C6DF711644

Q39151730-45AE0D24-D498-4C3F-ABDF-F4D2B765F506

Q39151730-61D2075D-AC5E-4509-A2E5-85D668D33813

Q39151730-63F54A4D-C689-4604-892C-6D7F34588A73

Q39151730-6B41D36E-71B4-474C-A846-D0695D3A9AB6

Q39151730-7EB8021E-D29D-43DB-81DC-18754FE161EF

Q39151730-809F56B1-BFEA-400C-A4D4-E762559231E8

P304

Q39151730-F618319B-FE5C-4B74-A58A-A6E0E820F3FA

P31

Q39151730-71614AE8-2F14-44DE-B674-46B55717CFAD

P356

Q39151730-FBD5E045-818B-4FFB-9691-758C8D803CD1

P433

Q39151730-4C5E78BA-EE76-4EDD-A1B1-7D4ABF4F7B38

P478

Q39151730-E60F1A92-B771-4BA7-8883-88894E62FC61

P577

Q39151730-50B5153F-8F56-4529-A0D0-22975051E557

P5875

Q39151730-0DD96504-BB21-428F-A9B6-0651F7026713

P698

Q39151730-D7B8DC8F-3B5D-46FD-8A1A-2366BEB040DE

P932

Q39151730-3BD760D1-A767-4CAB-9EE0-88B1A7905212

P356

P1433

ACS Medicinal Chemistry Letters

P1476

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

@en

P2093

AnneMarie C Pferdekamper

http://www.w3.org/2001/XMLSchema#string

Anthony Vattay

http://www.w3.org/2001/XMLSchema#string

Dai Cheng

http://www.w3.org/2001/XMLSchema#string

Dong Han

http://www.w3.org/2001/XMLSchema#string

Fangxian Sun

http://www.w3.org/2001/XMLSchema#string

Jeffrey Tsao

http://www.w3.org/2001/XMLSchema#string

Jing Yuan

http://www.w3.org/2001/XMLSchema#string

Jiqing Jiang

http://www.w3.org/2001/XMLSchema#string

Joseph F Kelleher

http://www.w3.org/2001/XMLSchema#string

Juliet Williams

http://www.w3.org/2001/XMLSchema#string

P2860

The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog

Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome

Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened

Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists

Hedgehog signaling in animal development: paradigms and principles

Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926)

Developmental roles and clinical significance of hedgehog signaling

Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Hedgehog signalling in cancer formation and maintenance.

P304

130-134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ML1000307

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

231711984

http://www.w3.org/2001/XMLSchema#string

P698

24900187

http://www.w3.org/2001/XMLSchema#string

P932

4007689

http://www.w3.org/2001/XMLSchema#string